| Accession |
PRJCA016043 |
| Title |
SHR-1210-II/III-HCC:A randomized, parallel controlled, multicenter phase II/III clinical trial of anti-PD-1 antibody SHR-1210 in previously treated patients with advanced hepatocellular carcinoma |
| Relevance |
Medical |
| Data types |
clinical,image,Metabolic,Biomarker data
|
| Organisms |
Homo sapiens
|
| Description |
To evaluate the efficacy and safety of anti-PD-1 antibody SHR-1210 in patients with advanced hepatocellular carcinoma (HCC) previously treated with systemic therapy |
| Sample scope |
Multiisolate |
| Release date |
2023-04-05 |
| Grants |
| Agency |
program |
Grant ID |
Grant title |
| NA
|
|
NA
|
|
|
|
| Submitter |
wanqiu
liang (wanqiu.liang@hengrui.com)
|
| Organization |
Jiangsu Hengrui Pharmaceutical Co. LTD |
| Submission date |
2023-04-04 |
